JP2001524948A5 - - Google Patents

Download PDF

Info

Publication number
JP2001524948A5
JP2001524948A5 JP1998539593A JP53959398A JP2001524948A5 JP 2001524948 A5 JP2001524948 A5 JP 2001524948A5 JP 1998539593 A JP1998539593 A JP 1998539593A JP 53959398 A JP53959398 A JP 53959398A JP 2001524948 A5 JP2001524948 A5 JP 2001524948A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1998539593A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001524948A (ja
JP4339411B2 (ja
Filing date
Publication date
Priority claimed from US08/816,551 external-priority patent/US5773430A/en
Application filed filed Critical
Publication of JP2001524948A publication Critical patent/JP2001524948A/ja
Publication of JP2001524948A5 publication Critical patent/JP2001524948A5/ja
Application granted granted Critical
Publication of JP4339411B2 publication Critical patent/JP4339411B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP53959398A 1997-03-13 1998-02-26 疎水性テトラサイクリンによるセリンプロテイナーゼ阻害活性 Expired - Fee Related JP4339411B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/816,551 1997-03-13
US08/816,551 US5773430A (en) 1997-03-13 1997-03-13 Serine proteinase inhibitory activity by hydrophobic tetracycline
PCT/US1998/003782 WO1998040079A1 (en) 1997-03-13 1998-02-26 Serine proteinase inhibitory activity by hydrophobic tetracycline

Publications (3)

Publication Number Publication Date
JP2001524948A JP2001524948A (ja) 2001-12-04
JP2001524948A5 true JP2001524948A5 (enExample) 2005-12-02
JP4339411B2 JP4339411B2 (ja) 2009-10-07

Family

ID=25220936

Family Applications (1)

Application Number Title Priority Date Filing Date
JP53959398A Expired - Fee Related JP4339411B2 (ja) 1997-03-13 1998-02-26 疎水性テトラサイクリンによるセリンプロテイナーゼ阻害活性

Country Status (13)

Country Link
US (1) US5773430A (enExample)
EP (1) EP0975349B1 (enExample)
JP (1) JP4339411B2 (enExample)
KR (1) KR100530683B1 (enExample)
AT (1) ATE292972T1 (enExample)
AU (1) AU733308B2 (enExample)
CA (1) CA2283071C (enExample)
DE (1) DE69829748T2 (enExample)
DK (1) DK0975349T3 (enExample)
ES (1) ES2241124T3 (enExample)
NZ (1) NZ337578A (enExample)
PT (1) PT975349E (enExample)
WO (1) WO1998040079A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7688998A (en) * 1997-05-20 1998-12-11 Trustees Of Columbia University In The City Of New York, The Use of metalloproteinase inhibitors in the treatment and prevention of pulmonaryemphysema
US5977091A (en) * 1998-09-21 1999-11-02 The Research Foundation Of State University Of New York Method of preventing acute lung injury
US5998390A (en) * 1998-09-28 1999-12-07 The Research Foundation Of State University Of New York Combination of bisphosphonate and tetracycline
US6946453B2 (en) 1998-11-18 2005-09-20 Collagenex Pharmaceuticals, Inc. 4-dedimethylaminotracycline derivatives
US6506740B1 (en) 1998-11-18 2003-01-14 Robert A. Ashley 4-dedimethylaminotetracycline derivatives
US6887678B2 (en) * 1998-12-02 2005-05-03 Cindy L. Bristow Method for the quantitative determination of proteinase inhibitors
CA2372443C (en) * 1999-04-30 2010-07-13 Apt Pharmaceuticals, L.L.C. Local administration of anti-malarial agents for the treatment of inflammatory diseases
GB0004531D0 (en) * 2000-02-25 2000-04-19 Richards Andrew J M The treatment of respiratory diseases
US6627785B1 (en) * 2000-02-29 2003-09-30 Virginia Commwealth University Wound dressings with protease-lowering activity
US6503892B2 (en) 2000-04-26 2003-01-07 New England Medical Center Hospitals Inc. Method of using matrix metalloproteinase inhibitors in filtering blebs following glaucoma filtering surgery and in the treatment of ischemic damage to the retina and optic nerve
US20020132798A1 (en) * 2000-06-16 2002-09-19 Nelson Mark L. 7-phenyl-substituted tetracycline compounds
US7247704B2 (en) * 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
CA2447008A1 (en) * 2001-04-05 2002-10-24 Collagenex Pharmaceuticals, Inc. Controlled delivery of tetracycline compounds and tetracycline derivatives
WO2002099134A1 (en) * 2001-06-05 2002-12-12 Auckland Uniservices Limited Methods and compositions for assessment of pulmonary function and disorders
US20060194773A1 (en) * 2001-07-13 2006-08-31 Paratek Pharmaceuticals, Inc. Tetracyline compounds having target therapeutic activities
EP1408987B1 (en) * 2001-07-13 2013-04-10 Paratek Pharmaceuticals, Inc. Tetracycline compounds having target therapeutic activities
US20030181371A1 (en) * 2001-12-28 2003-09-25 Angiotech Pharmaceuticals, Inc. Compositions and methods of using collajolie
EP2311797A1 (en) 2002-01-08 2011-04-20 Paratek Pharmaceuticals, Inc. 4-dedimethylamino tetracycline compounds
JP2005526754A (ja) 2002-03-08 2005-09-08 パラテック ファーマシューティカルズ インコーポレイテッド アミノメチル置換されたテトラサイクリン化合物
EP1503981A4 (en) 2002-03-21 2007-08-15 Paratek Pharm Innc SUBSTITUTED TETRACYCLINE COMPOUNDS
WO2004006850A2 (en) 2002-07-12 2004-01-22 Paratek Pharmaceuticals, Inc 3, 10, AND 12a SUBSTITUTED TETRACYCLINE COMPOUNDS
US20040092491A1 (en) * 2002-11-09 2004-05-13 The Research Foundation Of State University Of New York Method of treating sepsis-induced ARDS
CA2521885C (en) * 2003-04-07 2013-06-25 Shire Laboratories, Inc. Once daily formulations of tetracyclines
EP1624866A2 (en) * 2003-05-16 2006-02-15 Arriva Pharmaceuticals, Inc. Treatment of respiratory disease by inhalation of synthetic matrix metalloprotease inhibitors
WO2005009943A2 (en) 2003-07-09 2005-02-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
JP4738333B2 (ja) 2003-07-09 2011-08-03 パラテック ファーマシューティカルズ インコーポレイテッド ９−アミノメチルテトラサイクリン化合物のプロドラッグ
EP2332904A3 (en) * 2004-01-15 2012-04-11 Paratek Pharmaceuticals, Inc. Derivatives of tetracycline compounds
JP2008518025A (ja) 2004-10-25 2008-05-29 パラテック ファーマシューティカルズ インコーポレイテッド ４−アミノテトラサイクリンおよびその使用の方法
WO2006047756A2 (en) 2004-10-25 2006-05-04 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
EP1896607A4 (en) * 2005-05-10 2009-12-16 Synergenz Bioscience Ltd METHOD AND COMPOSITIONS FOR THE ASSESSMENT OF LUNG FUNCTION AND RESPIRATORY DISEASE
JP2008545390A (ja) * 2005-05-19 2008-12-18 シナージェンズ バイオサイエンス リミティド 遺伝的多型を用いた肺癌を発達させるリスクの評価方法
WO2006123943A1 (en) * 2005-05-20 2006-11-23 Synergenz Bioscience Limited Methods of analysis of polymorphisms and uses thereof
CA2616224A1 (en) * 2005-07-21 2007-02-01 Paratek Pharmaceuticals, Inc. 10-substituted tetracyclines and methods of use thereof
US8795730B2 (en) * 2006-01-31 2014-08-05 David John Vachon Compositions and methods for promoting the healing of tissue of multicellular organisms
PL2120963T3 (pl) 2006-12-21 2019-05-31 Paratek Pharm Innc Podstawione związki tetracyklinowe do leczenia zaburzeń zapalnych skóry
IL270446B2 (en) * 2006-12-21 2023-10-01 Paratek Pharm Innc A tetracycline compound, a pharmaceutical preparation containing the tetracycline compound, and the tetracycline compound or the pharmaceutical preparation for the treatment of the tetracycline-responsive condition
EP2144870A2 (en) * 2007-04-27 2010-01-20 Paratek Pharmaceuticals, Inc. Methods for synthesizing and purifying aminoalkyl tetracycline compounds
WO2009009042A1 (en) * 2007-07-06 2009-01-15 Paratek Pharmaceuticals, Inc. Methods for synthesizing substituted tetracycline compounds
TWI585071B (zh) 2008-05-19 2017-06-01 派洛泰克藥物股份有限公司 四環素化合物之甲苯磺酸鹽及同素異形體
HUE026562T2 (hu) 2008-08-08 2016-06-28 Tetraphase Pharmaceuticals Inc C7-fluor-helyettesített tetraciklin vegyületek
JP2012501456A (ja) 2008-08-28 2012-01-19 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後のための方法および組成物
CN102459153A (zh) 2009-05-08 2012-05-16 四相制药公司 四环素类化合物
EP2470500B1 (en) 2009-08-28 2017-10-04 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
WO2011123536A1 (en) 2010-03-31 2011-10-06 Tetraphase Pharmaceuticals, Inc. Polycyclic tetracycline compounds
TR201902057T4 (tr) 2012-08-31 2019-03-21 Tetraphase Pharmaceuticals Inc Tetrasiklin bileşikleri.
MA46567A (fr) 2016-10-19 2019-08-28 Tetraphase Pharmaceuticals Inc Formes cristallines de l'éravacycline
WO2020097450A1 (en) 2018-11-09 2020-05-14 Tetraphase Pharmaceuticals, Inc. Polymorphic forms of a compound and uses thereof
EP4460313A4 (en) * 2022-01-04 2026-01-14 Univ New York State Res Found CMT-3 FORMULATIONS AND THEIR METHODS OF USE

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666897A (en) * 1983-12-29 1987-05-19 Research Foundation Of State University Inhibition of mammalian collagenolytic enzymes by tetracyclines
US4935412A (en) * 1983-12-29 1990-06-19 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
US4925833A (en) * 1983-12-29 1990-05-15 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis
US4704383A (en) * 1983-12-29 1987-11-03 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
USRE34656E (en) * 1983-12-29 1994-07-05 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of bone deficiency
US5308839A (en) * 1989-12-04 1994-05-03 The Research Foundation Of State University Of New York Composition comprising non-steroidal anti-inflammatory agent tenidap and effectively non-antibacterial tetracycline
JP3016587B2 (ja) * 1989-12-04 2000-03-06 ザ・リサーチ・ファンデーション・オブ・ステート・ユニバーシティ・オブ・ニューヨーク 非ステロイド抗炎症剤及びテトラサイクリンの配合
US5045538A (en) * 1990-06-28 1991-09-03 The Research Foundation Of State University Of New York Inhibition of wasting and protein degradation of mammalian muscle by tetracyclines
US5223248A (en) * 1991-02-11 1993-06-29 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing antiplaque properties
US5258371A (en) * 1992-05-29 1993-11-02 Kuraray Co., Ltd. Method to reduce connective tissue destruction
JPH06256280A (ja) * 1992-11-17 1994-09-13 Univ New York State 糖尿病における過度のコラーゲン架橋結合を阻害する非抗菌性化学修飾テトラサイクリンを含むテトラサイクリン
US5523297A (en) * 1993-03-02 1996-06-04 The Research Foundation Of State University Of New York Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
CA2170030A1 (en) * 1993-09-14 1995-03-23 Robert A. Lazarus Pharmaceutical compositions containing ecotin and homologs thereof
US5618792A (en) * 1994-11-21 1997-04-08 Cortech, Inc. Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase
GB9502152D0 (en) * 1995-02-03 1995-03-29 Zeneca Ltd Proline derivatives
US5789395A (en) * 1996-08-30 1998-08-04 The Research Foundation Of State University Of New York Method of using tetracycline compounds for inhibition of endogenous nitric oxide production

Similar Documents

Publication Publication Date Title
JP2000509635A5 (enExample)
JP2000509637A5 (enExample)
JP2000507042A5 (enExample)
JP2000509942A5 (enExample)
JP2000510751A5 (enExample)
JP2000509912A5 (enExample)
JP2000516839A5 (enExample)
JP2000509587A5 (enExample)
JP2000507369A5 (enExample)
JP2001521424A5 (enExample)
JP2001524111A5 (enExample)
JP2001500532A5 (enExample)
JP2002500665A5 (enExample)
JP2000510793A5 (enExample)
JP2000508022A5 (enExample)
JP2000508841A5 (enExample)
JP2001522504A5 (enExample)
JP2000508680A5 (enExample)
JP2002510413A5 (enExample)
JP2000509804A5 (enExample)
JP2000509853A5 (enExample)
JP2000509755A5 (enExample)
JP2001516254A5 (enExample)
JP2000510969A5 (enExample)
JP2000508102A5 (enExample)